BDSI: BioDelivery Sciences International, Inc. - Summary | Jitta

BioDelivery Sciences International, Inc.

NASDAQ:BDSI

Price
$3.64
Loss Chance
44.9%
4.51JITTA SCORE
44.38%Under Jitta Line
Jitta Ranking
11 / 1,041
330 / 4,594
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (70)
Recent Business Performance (87)
Financial Strength (56)
Return to Shareholders (22)
Competitive Advantage (62)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2018
Debt LevelHigh Long Term Debt
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
4.51
44.38%
2.04
285.53%
2.25
348.40%
Pharmaceuticals
5.17
1.53%
3.62
10.42%
4.47
14.32%
COMPANY DESCRIPTION
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.